Sustainability & Climate

A new class of painkillers promises the power of opioids with a far lower risk of addiction. Tris Pharma's cebranopadol could reshape pain management.

NeuroSense adds world-renowned expert Prof. Steven Arnold to its board, a major vote of confidence in its multi-target Alzheimer's drug, PrimeC.

The new venue near EpicCentral isn't just another opening; it's a strategic move in a competitive market, fueling local growth and redefining leisure.

The firm is now recruiting for a Phase 1 trial of HWK-007 and has submitted an IND for HWK-016, targeting tough lung, ovarian, and endometrial cancers.

With multiple clinical trials advancing and a savvy global expansion, RESTEM is poised to challenge the treatment paradigm for autoimmune disorders.

At CES 2026, Hitachi unveiled major AI alliances with NVIDIA and Google, betting its HMAX platform can embed intelligence into the world's core systems.

A new partnership leverages in vivo screening to find novel obesity targets, aiming to revolutionize a market projected to exceed $100 billion.

Cizzle Brands' $83.75M acquisition of Flow Water's manufacturing arm is a strategic masterstroke, creating a vertically integrated beverage powerhouse.

A new national reimbursement code for NeurAxis's IB-Stim therapy is set to revolutionize access for chronic GI pain patients, validating the technology.

After 30 years, CEO Jim Foster will retire, passing the torch to COO Birgit Girshick in a move that signals continuity and a new era of governance.

858 Therapeutics' novel PARG inhibitor offers new hope for patients with a deadly, drug-resistant form of ovarian cancer, accelerating its path to approval.

The Spanish epigenetics leader will showcase its advanced CNS and oncology pipeline at key January conferences, seeking partners and investor validation.

Collegium Pharmaceutical projects robust 2026 revenue fueled by its ADHD drug Jornay PM, savvy debt refinancing, and a proactive generic strategy.

Echo Water's new Echo One promises ultra-pure, hydrogen-rich water on demand. But is the cutting-edge science and technology worth the premium price tag?

The opioid treatment specialist projects over $1.1B in revenue, driven by its flagship drug SUBLOCADE and a major strategic overhaul in the U.S.

With an expanded Boehringer Ingelheim deal and a new CMO, Enara Bio is set to take its novel 'Dark Antigen' therapy into human trials in 2026.

The special mission aviation provider completes a buyout of Bain Capital, consolidating NTC Group's ownership and securing new capital to expand its services.

EF Adventures' new Tour de France tours let fans ride race routes and party with pros, setting a new standard for immersive sports tourism.

Rani Therapeutics starts Phase 1 trials for an oral obesity drug, challenging the injectable market with a novel delivery system and a dual-action compound.

With major backing from Goldman Sachs, a biotech firm is advancing a potentially life-changing gene therapy for a rare, progressive form of blindness.